X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with MUNDRA PORT & SEZ - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs ADANI PORTS & SEZ - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES ADANI PORTS & SEZ INDOCO REMEDIES/
ADANI PORTS & SEZ
 
P/E (TTM) x 43.7 20.8 209.7% View Chart
P/BV x 2.8 4.3 63.9% View Chart
Dividend Yield % 0.8 0.4 230.7%  

Financials

 INDOCO REMEDIES   ADANI PORTS & SEZ
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
ADANI PORTS & SEZ
Mar-17
INDOCO REMEDIES/
ADANI PORTS & SEZ
5-Yr Chart
Click to enlarge
High Rs360342 105.4%   
Low Rs249170 146.4%   
Sales per share (Unadj.) Rs119.040.8 292.1%  
Earnings per share (Unadj.) Rs8.418.8 44.4%  
Cash flow per share (Unadj.) Rs15.224.4 62.3%  
Dividends per share (Unadj.) Rs1.601.30 123.1%  
Dividend yield (eoy) %0.50.5 103.4%  
Book value per share (Unadj.) Rs70.784.6 83.5%  
Shares outstanding (eoy) m92.152,070.95 4.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.66.3 40.7%   
Avg P/E ratio x36.413.6 268.0%  
P/CF ratio (eoy) x20.010.5 191.0%  
Price / Book Value ratio x4.33.0 142.4%  
Dividend payout %19.16.9 277.2%   
Avg Mkt Cap Rs m28,083530,370 5.3%   
No. of employees `0006.01.4 446.1%   
Total wages/salary Rs m2,1673,831 56.6%   
Avg. sales/employee Rs Th1,817.062,375.1 2.9%   
Avg. wages/employee Rs Th359.02,831.8 12.7%   
Avg. net profit/employee Rs Th127.728,835.9 0.4%   
INCOME DATA
Net Sales Rs m10,96884,394 13.0%  
Other income Rs m4010,401 0.4%   
Total revenues Rs m11,00794,795 11.6%   
Gross profit Rs m1,56556,921 2.7%  
Depreciation Rs m63311,602 5.5%   
Interest Rs m6213,932 0.4%   
Profit before tax Rs m90941,789 2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m093 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1392,866 4.8%   
Profit after tax Rs m77139,015 2.0%  
Gross profit margin %14.367.4 21.2%  
Effective tax rate %15.36.9 222.4%   
Net profit margin %7.046.2 15.2%  
BALANCE SHEET DATA
Current assets Rs m5,725119,074 4.8%   
Current liabilities Rs m5,45465,559 8.3%   
Net working cap to sales %2.563.4 3.9%  
Current ratio x1.01.8 57.8%  
Inventory Days Days6228 218.9%  
Debtors Days Days7285 84.5%  
Net fixed assets Rs m5,307255,675 2.1%   
Share capital Rs m1844,142 4.4%   
"Free" reserves Rs m6,331171,118 3.7%   
Net worth Rs m6,516175,260 3.7%   
Long term debt Rs m1,323179,932 0.7%   
Total assets Rs m11,970435,851 2.7%  
Interest coverage x15.64.0 391.2%   
Debt to equity ratio x0.21.0 19.8%  
Sales to assets ratio x0.90.2 473.2%   
Return on assets %7.012.1 57.3%  
Return on equity %11.822.3 53.1%  
Return on capital %12.415.7 78.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1413,789 30.1%   
Net fx Rs m3,366-3,789 -88.8%   
CASH FLOW
From Operations Rs m88640,019 2.2%  
From Investments Rs m-1,706-25,794 6.6%  
From Financial Activity Rs m1,316-13,247 -9.9%  
Net Cashflow Rs m4971,080 46.0%  

Share Holding

Indian Promoters % 59.2 49.8 118.9%  
Foreign collaborators % 0.0 6.4 -  
Indian inst/Mut Fund % 12.5 14.4 86.8%  
FIIs % 6.0 23.9 25.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 5.5 407.3%  
Shareholders   12,805 308,354 4.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   KOTHARI PRODUCTS  INGERSOLL RAND  TATA INVEST. CORP.  INDIABULLS FIN. SER.  COMPACT DISC  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3%

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jun 22, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS